ArticleJournal of thrombosis and haemostasis : JTH2022
Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa.
Article in Journal of thrombosis and haemostasis : JTH, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 54 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Safety of factor XI inhibitors compared to factor X inhibitors in atrial fibrillation: a systematic review and meta-analysis.Journal of thrombosis and thrombolysis · 2025Pooled it
- Bibliometric analysis of postoperative deep vein thrombosis in total hip arthroplasty using CiteSpace.Frontiers in surgery · 2025Pooled it
- Evaluating the Safety and Efficacy of Asundexian in Cardiovascular Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisPooled it
- Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Milvexian in Healthy Chinese Adults.Drug design, development and therapy · 2025Trial
- Effect of Age, Sex, Renal Impairment and Hepatic Impairment on the Safety, Pharmacokinetics and Pharmacodynamics of Asundexian.Clinical pharmacokinetics · 2024Trial
- Factor XI(a) Inhibition in Secondary Stroke Prevention: On the Cusp of a New Anticoagulation Paradigm.ACS pharmacology & translational science · 2026Article
- A comprehensive multicenter study assessing the impact of abelacimab, asundexian, and milvexian on coagulation assays.Blood advances · 2026Article
- The OCEANIC trial journey: from failure to breakthrough?European heart journal. Cardiovascular pharmacotherapy · 2026Article
- Translational Development of Oral FXIa Inhibitors: A Systematic Review of Molecular Design, Pharmacology, and Indication-Specific Clinical Evidence.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Factor XI Inhibition for Ischemic Stroke Secondary Prevention: Pharmacology, Clinical Evidence, and Future Directions.Journal of clinical pharmacology · 2026Review
- Regio-selective sulfation of heparin mimicking polymers defines in vivo activity.bioRxiv : the preprint server for biology · 2026Article
- Inhibition of fibrinolysisResearch and practice in thrombosis and haemostasis · 2026Article
- A Snail Galactosed Glycosaminoglycan Inhibits Thrombosis without Affecting Hemostasis via Disrupting FIXa-FVIIIa Complex Generation.ACS central science · 2026Article
- Pharmacological Management of Thrombosis: Current State and Future Strategies.International journal of molecular sciences · 2026Review
- Biomimetic bilayer hydrogel coating with antithrombotic and anticalcification properties for cardiovascular tissue engineering application.Regenerative biomaterials · 2026Article
- Rationale, design and baseline characteristics of participants in the OCEANIC-STROKE trial of FXIa inhibition for secondary stroke prevention.European stroke journal · 2026Article
- Population Pharmacokinetics of Asundexian in People at Risk for Thromboembolic/Cardiovascular Events.CPT: pharmacometrics & systems pharmacology · 2025Article
- Factor XI inhibitors for the prevention and treatment of venous and arterial thromboembolism.Nature reviews. Cardiology · 2025Review
- Factor XI/XIa Inhibitors: Promising Agents for the Secondary Prevention of Ischemic StrokeBalkan medical journal · 2025Article
- Structure-based design and synthesis of novel FXIa inhibitors targeting the S2' subsite for enhanced antithrombotic efficacy.Molecular diversity · 2025Article
Corrections and comments
- Commented on by
- Erratum issuedCorrigendum.2022
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundActivated coagulation factor XI (FXIa) contributes to the development and propagation of thrombosis but plays only a minor role in hemostasis; therefore, it is an attractive antithrombotic target.
objectivesTo evaluate the pharmacology of asundexian (BAY 2433334), a small molecule inhibitor targeting FXIa, in vitro and in various rabbit models.
methodsThe effects of asundexian on FXIa activity, selectivity versus other proteases, plasma thrombin generation, and clotting assays were evaluated. Antithrombotic effects were determined in FeCl
resultsAsundexian inhibited human FXIa with high potency and selectivity. It reduced FXIa activity, thrombin generation triggered by contact activation or low concentrations of tissue factor, and prolonged activated partial thromboplastin time in human, rabbit, and various other species, but not in rodents. In the FeCl
conclusionsAsundexian is a potent oral FXIa inhibitor with antithrombotic efficacy in arterial and venous thrombosis models in prevention and intervention settings, without increasing bleeding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.